Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
Executive Summary
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
You may also be interested in...
NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck
NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.